2017
Proteomics and Dimerix partner to improve the treatment of kidney disease
04/12/2017Proteomics joins major health study to target lung disease
28/11/2017Results of Meeting
28/11/2017Proteomics AGM Presentation
27/11/2017PromarkerD predictive diagnostic test to launch in Q1 2018
22/11/2017Proteomics strengthens Board and Business Development team
03/11/2017Appendix 3B – Issue of Employee Options
27/10/2017Notice of Annual General Meeting
26/10/2017Proteomics partnered consortium to receive $2 million
25/10/2017Appendix 4C – September 2017 Quarterly Report
10/10/2017Proteomics receives R&D tax incentive
14/09/2017Change of Director’s Interest Notice
06/09/2017PromarkerD predictive test results published – Diabetes Care
31/08/2017Annual Report to shareholders
31/08/2017Corporate Governance Statement and Appendix 4G
31/08/2017Appendix 4E – Preliminary Final Report
22/08/2017Appendix 3B
17/08/2017Results of Extraordinary General Meeting
16/08/2017US PromarkerD patent expanded to all kidney disease
17/07/2017Appendix 3B
14/07/2017Proteomics wins major analytical services contract
13/07/2017Notice of Extraordinary General Meeting/Proxy Form
13/07/2017Letter to Shareholders
13/06/2017Clinical validation study confirms PromarkerD performance
09/05/2017World leading laboratory launches clinical trials testing
27/04/2017Appendix 4C – March 2017 Quarterly Report
18/04/2017Appendix 3B
12/04/2017Update on voluntary escrow and ASIC relief
11/04/2017Research Report and Investor Briefing
04/04/2017PromarkerD update
31/03/2017Release from mandatory escrow and proposed voluntary escrow
27/03/2017Frost & Sullivan- PromarkerD diagnostic test world leading
21/03/2017Proteomics targets diabetic kidney disease in Asia
21/03/2017Proteomics presents at Asia Biotech Invest 2017
08/02/2017Diabetic kidney disease diagnostic test data published
13/01/2017Appendix 3Y
04/01/2017Change in Substantial Holding
03/01/2017Change in Substantial Holding
